Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.47 |
| ▸ | STK17B | O94768 | 1/20 | 0.39 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 4/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | CKS1B | P61024 | 1/20 | 0.37 |
| ▸ | SKP1 | P63208 | 1/20 | 0.37 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.37 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 3/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7706040 | 0.84 | PIK3CD (0.44) | PIK3CDKMT2AL3MBTL1BTKJAK3 | |
| SCHEMBL2634656 | 0.83 | PIK3CD (0.35) | PIK3CDBTK | |
| SCHEMBL18101480 | 0.81 | PIK3CD (0.43) | PIK3CDKMT2AL3MBTL1BTKJAK3 | |
| SCHEMBL26180336 | 0.81 | PIK3CD (0.52) | PIK3CDKMT2AL3MBTL1BTKJAK3 | |
| SCHEMBL16524018 | 0.80 | BTK (0.46) | PIK3CDSTK17BSTK17AKMT2AL3MBTL1 | |
| SCHEMBL2634479 | 0.78 | PDE10A (0.42) | PIK3CDSTK17BSTK17AKMT2AL3MBTL1 | |
| SCHEMBL7701039 | 0.78 | PIK3CD (0.46) | PIK3CDKMT2AL3MBTL1BTKJAK3 | |
| SCHEMBL7700876 | 0.78 | PIK3CD (0.46) | PIK3CDKMT2AL3MBTL1BTKJAK3 | |
| SCHEMBL7694399 | 0.78 | PIK3CD (0.45) | PIK3CDKMT2AL3MBTL1BTKCKS1B | |
| SCHEMBL14230902 | 0.77 | PIK3CD (0.44) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160280703-A1 | Heteroaryloxycarbocyclyl Compounds as PDE 10 Inhibitors | AMGEN INC. | 2016-09-29 | — | — | US | disclosed |
| US-20160280703-A1 | Heteroaryloxycarbocyclyl Compounds as PDE 10 Inhibitors | AMGEN INC. | 2016-09-29 | — | — | US | disclosed |
| US-20160280703-A1 | Heteroaryloxycarbocyclyl Compounds as PDE 10 Inhibitors | AMGEN INC. | 2016-09-29 | — | — | US | disclosed |
| US-8952037-B2 | Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors | AMGEN INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8952037-B2 | Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors | AMGEN INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8952037-B2 | Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors | AMGEN INC. (US) | 2015-02-10 | — | — | US | disclosed |
| EP-2569306-A1 | HETEROARYLOXYCARBOCYCLYL COMPOUNDS AS PDE10 INHIBITORS | Amgen Inc. (US) | 2013-03-20 | — | — | EP | disclosed |
| US-20110306591-A1 | HETEROARYLOXYCARBOCYCLYL COMPOUNDS AS PDE10 INHIBITORS | INC., AMGEN | 2011-12-15 | — | — | US | disclosed |
| US-20110306591-A1 | HETEROARYLOXYCARBOCYCLYL COMPOUNDS AS PDE10 INHIBITORS | INC., AMGEN | 2011-12-15 | — | — | US | disclosed |
| US-20110306591-A1 | HETEROARYLOXYCARBOCYCLYL COMPOUNDS AS PDE10 INHIBITORS | INC., AMGEN | 2011-12-15 | — | — | US | disclosed |
| WO-2011143366-A1 | HETEROARYLOXYCARBOCYCLYL COMPOUNDS AS PDE10 INHIBITORS | AMGEN INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143366-A1 | HETEROARYLOXYCARBOCYCLYL COMPOUNDS AS PDE10 INHIBITORS | AMGEN INC. (US) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306591-A1 | HETEROARYLOXYCARBOCYCLYL COMPOUNDS AS PDE10 INHIBITORS | PDE10A, PDE9A, HDAC10 | PIK3CD 93/4885STK17B 3373/4885STK17A 2930/4885 |
| US-20160280703-A1 | Heteroaryloxycarbocyclyl Compounds as PDE 10 Inhibitors | PDE10A, PDE9A, PDE7A | PIK3CD 79/4885STK17B 3355/4885STK17A 2876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.